文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

法布里病:长期酶替代治疗下左心室肥厚仍可发生进展

Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy.
PubMed 文献 · Heart · 2024-07-10

研究纳入瑞士Fabry队列中接受酶替代治疗并随访至少5年的60例法布里病患者,中位随访10.5年。结果36%的患者左心室质量指数仍进展,31%发生主要法布里病相关事件,治疗开始时已有左心室肥厚是进展和不良事件的强预测因素。

要点

  • 长期酶替代治疗下36%患者左心室质量指数仍进展。
  • 治疗开始时已有左心室肥厚与后续进展及不良事件相关。
  • 主要不良事件者以年龄较大的男性及基线左心室肥厚者为主。

核心结论

  • 在酶替代治疗下中位随访超过10年,36%的法布里病患者仍出现左心室质量指数进展。
  • 32%的患者发生主要法布里病相关事件,以年龄较大的男性为主。
  • 治疗开始时存在左心室肥厚是酶替代治疗下左心室质量指数进展和不良事件的强预测因素。

研究设计与样本

  • 来自Independent Swiss-Fabry Cohort的连续法布里病患者,接受酶替代治疗且至少随访5年。
  • 共纳入60例患者,年龄35(23-48)岁,男性39例(65%),随访10.5(7.2-12.2)年。
  • 心脏进展定义为首次与末次随访经胸超声心动图之间左心室质量指数增加>10 g/m2。

主要发现

  • 22例(36%,年龄34±15岁)出现左心室质量指数进展,进展速率为12.1(7-17.6)g/m2每100患者年。
  • 进展者中7例(11%,年龄29±13岁)基线无左心室肥厚,其中3例进展为左心室肥厚。
  • 左心室质量指数进展多见于男性(39例中17例(43%)vs 21例中5例(24%),p<0.01)及30岁以后(22例中17例(77%))。
  • 治疗开始时左心室肥厚与左心室质量指数进展相关(OR 1.3,95%CI 1.1至2.6;p=0.02)。
  • 19例(31%)发生主要法布里病相关事件,其中男性17例(89%),年龄较大(45±11 vs 32±9岁),基线左心室肥厚12例(63%),10例(52%)伴有左心室质量指数进展。

临床怎么用

  • 对接受酶替代治疗的法布里病患者应长期监测左心室质量指数,尤其治疗开始时已有左心室肥厚者。
  • 男性及30岁以上患者左心室质量指数进展风险较高,需加强心脏随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzyme replacement therapy (ERT) may halt or attenuate disease progression in patients with Anderson-Fabry disease (AFD). However, whether left ventricular hypertrophy (LVH) can be prevented by early therapy or may still progress despite ERT over a long-term follow-up is still unclear. METHODS: Consecutive patients with AFD from the Independent Swiss-Fabry Cohort receiving ERT who were at least followed up for 5 years were included. Cardiac progression was defined as an increase of >10 g/m2 in left ventricular mass index (LVMI) between the first and the last available follow-up transthoracic echocardiography. RESULTS: 60 patients (35 (23-48) years, 39 (65%) men) were followed up for 10.5 (7.2-12.2) years. 22 had LVH at ERT start (LVMI of 150±38 g/m2). During follow-up, 22 (36%, 34±15 years) had LVMI progression of 12.1 (7-17.6) g/m2 per 100 patient-years, of these 7 (11%, 29±13 years) with no LVH at baseline. Three of them progressed to LVH. LVMI progression occurred mostly in men (17 of 39 (43%) vs 5 of 21 (24%), p<0.01) and after the age of 30 years (17 of 22 (77%)). LVH at ERT start was associated with LVMI progression (OR 1.3, 95% CI 1.1 to 2.6; p=0.02). A total of 19 (31%) patients experienced a major AFD-related event. They were predominantly men (17 of 19, 89%), older (45±11 vs 32±9 years) with baseline LVH (12 of 19, 63%), and 10 of 19 (52%) presented with LVMI progression. CONCLUSIONS: Over a median follow-up of >10 years under ERT, 36% of the patients still had LVMI cardiac progression, and 32%, predominantly older men, experienced major AFD-related events. LVH at treatment initiation was a strong predictor of LVMI progression and adverse events on ERT.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Maurizi N, Nowak A, Gruner C, et al. Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy. Heart. 2024. PMID: 38749654. doi:10.1136/heartjnl-2024-323975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。